PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Iovance Biotherapeutics, Inc. (IOVA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS4622601007
CUSIP462260100
SectorHealthcare
IndustryBiotechnology
IPO DateOct 15, 2010

Highlights

Market Cap$3.40B
EPS (TTM)-$1.67
Total Revenue (TTM)$32.30M
Gross Profit (TTM)-$31.06M
EBITDA (TTM)-$310.41M
Year Range$3.76 - $18.33
Target Price$23.92
Short %21.98%
Short Ratio14.23

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons: IOVA vs. ATAI, IOVA vs. RARE, IOVA vs. IDYA, IOVA vs. CORT, IOVA vs. ET, IOVA vs. MATW, IOVA vs. AXSM

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Iovance Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%JuneJulyAugustSeptemberOctoberNovember
-17.59%
10.27%
IOVA (Iovance Biotherapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Iovance Biotherapeutics, Inc. had a return of 40.71% year-to-date (YTD) and 171.73% in the last 12 months. Over the past 10 years, Iovance Biotherapeutics, Inc. had an annualized return of 5.37%, while the S&P 500 had an annualized return of 10.92%, indicating that Iovance Biotherapeutics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date40.71%19.77%
1 month9.37%-0.67%
6 months-17.58%10.27%
1 year171.73%31.07%
5 years (annualized)-11.68%13.22%
10 years (annualized)5.37%10.92%

Monthly Returns

The table below presents the monthly returns of IOVA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-4.92%105.82%-6.85%-20.51%-24.62%-9.68%8.85%33.56%-19.47%11.18%40.71%
202324.57%-8.42%-16.19%-7.69%54.96%-19.45%3.13%-16.80%-24.67%-16.04%58.90%33.94%27.23%
2022-12.78%-5.89%6.25%-9.01%-55.45%63.56%5.53%-7.98%-10.63%-2.51%-31.48%-0.16%-66.53%
2021-5.52%-14.92%-15.12%-0.69%-40.94%40.12%-14.41%8.08%2.45%-1.42%-22.99%1.98%-58.86%
2020-21.46%51.38%-9.02%7.38%-0.19%-14.46%5.90%14.65%-1.23%8.38%8.77%19.56%67.63%
20193.39%12.24%-7.40%19.87%43.42%49.97%0.29%-14.56%-13.37%16.10%8.05%21.24%212.77%
201894.37%11.58%-2.59%-14.20%0.69%-12.33%10.94%24.65%-36.44%-19.29%6.50%-8.48%10.62%
20174.32%5.52%-2.61%-8.05%-24.82%42.72%-20.41%-1.71%34.78%0.39%16.32%-11.60%15.11%
2016-22.41%-6.84%-8.96%11.61%4.06%37.29%9.14%-9.95%3.39%-24.06%6.40%4.51%-9.97%
2015-0.25%14.39%34.86%-1.49%-6.20%-18.05%-6.65%-16.94%-18.99%12.33%12.52%6.04%-1.91%
2014-53.05%11.97%71.01%-8.90%-12.79%-14.67%11.72%-3.78%3.92%-10.63%-3.76%27.97%-25.05%
2013-50.00%-27.27%-25.00%-66.67%150.00%-60.00%250.00%-14.29%9.17%-27.48%77.26%24.70%-52.27%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of IOVA is 86, placing it in the top 14% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of IOVA is 8686
Combined Rank
The Sharpe Ratio Rank of IOVA is 9090Sharpe Ratio Rank
The Sortino Ratio Rank of IOVA is 8989Sortino Ratio Rank
The Omega Ratio Rank of IOVA is 8383Omega Ratio Rank
The Calmar Ratio Rank of IOVA is 8888Calmar Ratio Rank
The Martin Ratio Rank of IOVA is 7777Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


IOVA
Sharpe ratio
The chart of Sharpe ratio for IOVA, currently valued at 2.12, compared to the broader market-4.00-2.000.002.002.12
Sortino ratio
The chart of Sortino ratio for IOVA, currently valued at 3.03, compared to the broader market-4.00-2.000.002.004.003.03
Omega ratio
The chart of Omega ratio for IOVA, currently valued at 1.35, compared to the broader market0.501.001.502.001.35
Calmar ratio
The chart of Calmar ratio for IOVA, currently valued at 2.00, compared to the broader market0.002.004.006.002.00
Martin ratio
The chart of Martin ratio for IOVA, currently valued at 5.67, compared to the broader market-10.000.0010.0020.0030.005.67
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.67, compared to the broader market-4.00-2.000.002.002.67
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.55, compared to the broader market-4.00-2.000.002.004.003.55
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.50, compared to the broader market0.501.001.502.001.50
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 3.45, compared to the broader market0.002.004.006.003.45
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 17.04, compared to the broader market-10.000.0010.0020.0030.0017.04

Sharpe Ratio

The current Iovance Biotherapeutics, Inc. Sharpe ratio is 2.12. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Iovance Biotherapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
2.12
2.67
IOVA (Iovance Biotherapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Iovance Biotherapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-92.81%
-2.59%
IOVA (Iovance Biotherapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Iovance Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Iovance Biotherapeutics, Inc. was 99.37%, occurring on Apr 12, 2013. The portfolio has not yet recovered.

The current Iovance Biotherapeutics, Inc. drawdown is 92.81%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.37%Jun 8, 2011464Apr 12, 2013
-13.51%Nov 16, 20104Nov 19, 20107Dec 1, 201011
-12.7%Mar 9, 20114Mar 14, 201133Apr 29, 201137
-9.09%Oct 19, 20104Oct 22, 20105Oct 29, 20109
-7.56%Dec 6, 20103Dec 8, 20104Dec 14, 20107

Volatility

Volatility Chart

The current Iovance Biotherapeutics, Inc. volatility is 17.22%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%JuneJulyAugustSeptemberOctoberNovember
17.22%
3.11%
IOVA (Iovance Biotherapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Iovance Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Iovance Biotherapeutics, Inc..


Loading data...

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items